JAK2 and myeloproliferative neoplasm: It is plausible that individuals with SVT who carry the JAK2 V617F mutation but do not exhibit obvious clinical manifestations of myeloproliferative neoplasms may represent a unique MPN subtype or an early stage of the disease, and these SVTs may manifest during the early phase of MPNs, preceding the development of overt clinical characteristics.